Entering text into the input field will update the search result below

Why did ImmunoGen stock rocket today? Ovarian cancer drug data

May 03, 2023 5:47 PM ETImmunoGen, Inc. (IMGN)By: Jonathan Block, SA News Editor
Stock financial index show successful investment on solar energy for renewable energy industrial business with graph and chart data on solar panels installation background for presentation and report

ekapol/iStock via Getty Images

  • ImmunoGen stock closed up a whopping ~136% on Wednesday after presenting data indicating significant improvement in progression-free and overall survival for ovarian cancer drug Elahere (mirvetuximab soravtansine-gynx).
  • The company said that median PFS in the Elahere group was 5.62 months, compared to 3.98 months in the chemo group.
  • The antibody-drug conjugate received accelerated approval in November 2022.
  • ImmunoGen (NASDAQ:IMGN) now has an over $2B market cap.

Recommended For You

Comments

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.